G

c

้เก

1-29-01

Attorney Docket No. 4099-0003.31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Certification under 37 CFR \$1.10 (if applicable)

EL 530 374 098 US Express Mail Label Number

January 26, 2001 Date of Deposit

I hereby certify that this Transmittal Letter, enclosed application and any other documents referred to as enclosed herein, are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR \$1.10 on the date above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Deborah H. Brockmeyer
(Print Name of Person Mailing Application)



Transmittal of Continuation-in-Part Patent Application for Filing Under 37 CFR §1.53(b)

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

Sir: Transmitted herewith for filing is a patent application by inventor(s): Allan S. Lau, Natalya Ossina, Kenneth Hoyt and entitled:

HIGH LEVEL CYTOKINE PRODUCTION WITH ENHANCED CELL VIABILITY

- Enclosed are:
 - One stamped, self-addressed postcard for PTO datestamp.
 - Certificate of Express Mail.
 - One utility patent application containing text pages $1-\underline{41}$ and $\underline{5}$ Sheets of drawings.
 - Declaration of Inventorship (unsigned)
- 2. Amendment
 - Please enter the enclosed Preliminary Amendment before calculating the filing fee. It is understood that only amendments reducing the number of claims will be entered for this purpose.
 - Please cancel original claims *, inclusive, before calculating the filing fee. (At least one original independent claim should be retained for filing purposes.)
- Extension of Time
 - A petition for extension of time has been filed in the parent to extend the pendency of the parent to * (copy enclosed).
- 4. U.S. Priority
 - This application is a continuation-in-part of Ser. No. 09/657,881 filed September 8, 2000, now pending, which claims priority of Ser. No. 60/152,854 filed September 8, 1999, now abandoned, both of which are incorporated herein in their entirety by reference.
- 5. Foreign Priority
 - Priority of Application No. $\underline{\star}$ filed in $\underline{\star}$ on $\underline{\star}$ is claimed under 35 USC \$119.
 - $\ \square$ A certified copy of this priority document is enclosed.

6. Prior Documents Still In Effect

- This application and parent application Serial No. 09/657,881 filed September 8, 2000 are assigned to GeneTrol Biotherapeutics, Inc. as evidenced by an Assignment and Assignment Recordation Cover Sheet submitted to the U.S. Patent and Trademark Office for recording on November 20, 2000.
- Power of Attorney in the above-identified prior application is to <u>Linda R. Judge</u>, Reg. No. 42,702, and the other attorneys or agents identified therein.

7. Entity Status

Applicant claims small entity status. See 37 CFR §1.27

8. Fees

2

The filing fee has been calculated taking into account any amendments in section 2 above:

1	(Col. 1)	(Col. 2)	Small Entity Rate Pee,		T .	Other Than a Small Entity	
For:	No. Filed					Rate	Pee
Basic Fee				\$355.00	or		\$710.00
Total Claims	19 - 20	0	0 x \$ 9 =	\$ 00.00	or	x \$ 18 =	ş
Independent Claims	3 - 3	0	0 x \$40 =	\$ 00.00	or	x \$ 80 =	ş
Multiple Dependent Claim Presented			+ \$135 =	\$135.00	or	+ \$270 =	s
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.			TOTAL	\$490.00	or	TOTAL	\$

- A check in the amount of \$490.00 is enclosed to cover the Filing Fee. The Commissioner is hereby authorized to charge any deficiency in fees under 37 CFR 1.16 and 1.17 to Deposit Account 04-0531.
- \square Please charge the Filing Fee and any other fees necessary for timely filing of this application to Deposit Account 04-0531
- *Filing fee to be submitted in response to anticipated receipt of Notice to File Missing Parts. DO NOT CHARGE DEPOSIT ACCOUNT.

Respectfully submitted,

Date: _______26, 2001

Registration No. 42,702

Correspondence Address:

Customer No. 22918 (650) 324-0880